Observation of clinical characteristics of membranoproliferative glomerulonephritis with monoclonal immunoglobulin deposition

doi:10.11958/20260051

Abstract

Abstract:

Objective To analyze the clinical and pathological characteristics, treatment modalities and prognosis of proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID), and to offer references for the diagnosis and treatment of this disease. Methods A retrospective analysis was conducted on the clinical data, pathological manifestations, treatment regimens and prognostic characteristics of three patients with PGNMID diagnosed by renal biopsy in our hospital. The aim was to explore the pathogenesis and evaluate the efficacy of different treatment methods. Results All 3 PGNMID patients were female, with an average age of (68.00 ± 12.29) years. Throughout the disease course, all patients exhibited glomerular hematuria, massive proteinuria and varying degrees of renal function impairment. Histopathological examination under light microscopy indicated membranoproliferative glomerulonephritis. Immunofluorescence demonstrated the deposition of IgG subtype immunoglobulins and light chains in the capillary loops and mesangial regions, accompanied by complement C3 deposition. Electron microscopy revealed diffuse fusion of podocytes (>95%) and electron-dense material deposition in the subendothelial and mesangial regions. In 2 cases, electron-dense material deposition was also observed in the basement membrane. All three patients received a combination of renin-angiotensin-converting enzyme inhibitors (RASi) and clonal targeted therapy. One month later, their 24-hour urinary protein levels showed varying degrees of reduction. Two patients achieved partial response (PR) after 2-3 months of treatment, achieved complete response (CR) in the 6th to 7th month. One patient maintained PR during the follow-up period up to the month 6. Conclusion Patients with PGNMID usually present with nephrotic syndrome accompanied by renal function decline. Pathologically, it is often characterized by membranoproliferative glomerulonephritis with IgG3 deposition. Early diagnosis and treatment can lead to better clinical therapeutic outcomes.

Key words: glomerulonephritis, membranoproliferative, antibodies, monoclonal, immunoglobulin G, pathology, rituximab, proliferative glomerulonephritis with monoclonal immunoglobulin deposition, targeted therapy

CLC Number:

R692.31

Figures/Tables 7

References 27

[1]	Li M, Xu G. An update of proliferative glomerulonephritis with monoclonal immunoglobulin deposits[J]. Clin Kidney J, 2022, 15(6):1041-1048. doi:10.1093/ckj/sfab269.
[2]	Gumber R, Cohen J B, Palmer M B, et al. A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits[J]. Kidney Int, 2018, 94(1):199-205. doi:10.1016/j.kint.2018.02.020.
[3]	Zhou H, Li M, Zeng C, et al. Efficacy of immunomodulatory drugs in combination with dexamethasone in proliferative glomerulonephritis with monoclonal immunoglobulin deposits[J]. Kidney Int Rep, 2022, 7(10):2166-2175. doi:10.1016/j.ekir.2022.07.009.
[4]	Bridoux F, Javaugue V, Nasr S H, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits:a nephrologist perspective[J]. Nephrol Dial Transplant, 2021, 36(2):208-215. doi:10.1093/ndt/gfz176.
[5]	Hou J, Haas M. Seeing the light(chains):a paradigm shift in PGNMID[J]. Kidney Int, 2025, 108(6):996-998. doi:10.1016/j.kint.2025.09.018.
[6]	Fourdinier O, Ulrich M, Karras A, et al. Glomerulonephritis with non-Randall-type,non-cryoglobulinaemic monoclonal immunoglobulin G deposits(PGNMID and ITG)[J]. Clin Kidney J, 2022, 15(9):1727-1736. doi:10.1093/ckj/sfac085.
[7]	Kousios A, Duncan N, Tam F W K, et al. Proliferative glomerulonephritis with monoclonal Ig deposits(PGNMID):diagnostic and treatment challenges for the nephrologist![J]. Kidney Int, 2019, 95(2):467-468. doi:10.1016/j.kint.2018.10.016.
[8]	Strati P, Nasr S H, Leung N, et al. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis:the Mayo Clinic experience[J]. Haematologica, 2015, 100(9):1180-1188. doi:10.3324/haematol.2015.128793.
[9]	Best Rocha A, Larsen C P. Membranous glomerulopathy with light chain-restricted deposits:A clinicopathological analysis of 28 cases[J]. Kidney Int Rep, 2017, 2(6):1141-1148. doi:10.1016/j.ekir.2017.07.008.
[10]	Liu M, Yu X, Wang S, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits:an entity associated with distinct diseases and comparison between IgG1 and IgG3 subtypes[J]. J Nephrol, 2022, 35(9):2363-2372. doi:10.1007/s40620-022-01317-w.
[11]	Aucouturier P, D'Agati V D, Ronco P. A fresh perspective on monoclonal gammopathies of renal significance[J]. Kidney Int Rep, 2021, 6(8):2059-2065. doi:10.1016/j.ekir.2021.04.026.
[12]	Bu L, Valeri A M, Said S M, et al. IgM variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits:A case series[J]. Am J Kidney Dis, 2025, 85(6):716-726.e1. doi:10.1053/j.ajkd.2025.01.009.
[13]	Javaugue V, Pascal V, Nasr S H, et al. Revisiting proliferative glomerulonephritis with monoclonal immunoglobulin deposits through immunoglobulin repertoire sequencing[J]. Kidney Int, 2025, 108(6):1146-1157. doi:10.1016/j.kint.2025.07.039.
[14]	Gowda K K, Nada R, Ramachandran R, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin deposition disease:The utility of routine staining with immunoglobulin light chains[J]. Indian J Nephrol, 2015, 25(6):344-348. doi:10.4103/0971-4065.151354.
[15]	Xing G, Gillespie R, Bedri B, et al. Proliferative glomerulonephritis with monoclonal IgG deposits in children and young adults[J]. Pediatr Nephrol, 2018, 33(9):1531-1538. doi:10.1007/s00467-018-3949-8.
[16]	Gozzetti A, Guarnieri A, Zamagni E, et al. Monoclonal gammopathy of renal significance(MGRS):Real-world data on outcomes and prognostic factors[J]. Am J Hematol, 2022, 97(7):877-884. doi:10.1002/ajh.26566.
[17]	Santana De Roberts R, Batal I, Aljareh A, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits associated with parvovirus B19[J]. BMJ Case Rep, 2021, 14(6):e243061. doi:10.1136/bcr-2021-243061.
[18]	Nasr S H, Javaugue V. Insights into proliferative glomerulonephritis with monoclonal immunoglobulin deposits-is it really monoclonal or not?[J]. Curr Opin Nephrol Hypertens, 2025, 34(3):199-205. doi:10.1097/MNH.0000000000001061.
[19]	Amaador K, Peeters H, Minnema M C, et al. Monoclonal gammopathy of renal significance(MGRS)histopathologic classification, diagnostic workup, and therapeutic options[J]. Neth J Med, 2019, 77(7):243-254.
[20]	Zand L, Rajkumar S V, Leung N, et al. Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits[J]. J Am Soc Nephrol, 2021, 32(5):1163-1173. doi:10.1681/ASN.2020101541.
[21]	Ji Q, Yu S, Zhou X, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits(PGNMID):three case reports and systematic review[J]. Front Med(Lausanne), 2025, 12:1637435. doi:10.3389/fmed.2025.1637435.
[22]	Bhutani G, Nasr S H, Said S M, et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits[J]. Mayo Clin Proc, 2015, 90(5):587-596. doi:10.1016/j.mayocp.2015.01.024.
[23]	Fermand J P, Bridoux F, Kyle R A, et al. How I treat monoclonal gammopathy of renal significance(MGRS)[J]. Blood, 2013, 122(22):3583-3590. doi:10.1182/blood-2013-05-495929.
[24]	Lin L, Chen N. A Review on the diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits[J]. Int J Gen Med, 2022, 15:8577-8582. doi:10.2147/IJGM.S386733.
[25]	Oki R, Unagami K, Taneda S, et al. Treatment with bortezomib for recurrent proliferative glomerulonephritis with monoclonal IgG deposits in kidney allograft. Case report and review of the literature[J]. J Nephrol, 2022, 35(4):1289-1293. doi:10.1007/s40620-022-01332-x.
[26]	Liu M Y, Yu X J, Wang S X, et al. Characteristics of complement protein deposition in proliferative glomerulonephritis with monoclonal immunoglobulin deposition[J]. Clin J Am Soc Nephrol, 2023, 18(12):1573-1582. doi:10.2215/CJN.0000000000000295.
[27]	Guiard E, Karras A, Plaisier E, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits:correlation with IgG subclass and response to rituximab[J]. Clin J Am Soc Nephrol, 2011, 6(7):1609-1616. doi:10.2215/CJN.10611110.

病例		年龄/岁		基本病情				血尿/HPF	24 h UTP/ （g/d）			ALB/ （g/L）		SCr/ （μmol/L）		eGFR/ [mL/（min·1.73m²）]
1		54		颜面部水肿1年，加重1个月				满视野	5.07			35.00		85.00		70.17
2		73		发现Scr升高3个月，双下肢水肿2个月				57.00	6.30			26.80		108.00		46.78
3		77		确诊膜增生性肾炎15年，蛋白尿加重3个月				10.20	11.24			27.20		262.00		15.75
病例	Hb/ （g/L）		血κ轻链/（g/L）		血λ轻链/（g/L）	κ/λ	抗核抗体谱			免疫固定电泳	血清IgG/（g/L）		补体C3/（g/L）		补体C4/（g/L）		骨髓活检浆细胞数/个
1	99		5.44		2.58	2.11	抗SSA/Ro（+++）、抗Ro-52抗体（+++）			阴性	23.80		0.60		0.09		1
2	108		1.87		0.68	2.75	抗SSA/Ro（+++）、抗Ro-52抗体（+++）			阴性	7.70		0.93		0.30		2
3	108		1.35		1.03	1.31	抗SSA/Ro（+++）、抗Ro-52抗体（++）			阴性	6.83		0.94		0.34		1

病例		年龄/岁		基本病情				血尿/HPF	24 h UTP/ （g/d）			ALB/ （g/L）		SCr/ （μmol/L）		eGFR/ [mL/（min·1.73m²）]
1		54		颜面部水肿1年，加重1个月				满视野	5.07			35.00		85.00		70.17
2		73		发现Scr升高3个月，双下肢水肿2个月				57.00	6.30			26.80		108.00		46.78
3		77		确诊膜增生性肾炎15年，蛋白尿加重3个月				10.20	11.24			27.20		262.00		15.75
病例	Hb/ （g/L）		血κ轻链/（g/L）		血λ轻链/（g/L）	κ/λ	抗核抗体谱			免疫固定电泳	血清IgG/（g/L）		补体C3/（g/L）		补体C4/（g/L）		骨髓活检浆细胞数/个
1	99		5.44		2.58	2.11	抗SSA/Ro（+++）、抗Ro-52抗体（+++）			阴性	23.80		0.60		0.09		1
2	108		1.87		0.68	2.75	抗SSA/Ro（+++）、抗Ro-52抗体（+++）			阴性	7.70		0.93		0.30		2
3	108		1.35		1.03	1.31	抗SSA/Ro（+++）、抗Ro-52抗体（++）			阴性	6.83		0.94		0.34		1

病例	免疫荧光		超微结构电子致密物位	光镜
病例	优势蛋白类型及位置	补体类型	超微结构电子致密物位	肾小球病变类型	嗜复红物质沉积位置
1	IgG2-Lambda；团块状/毛细血管襻、系膜区	C3（+）、C4（+/-）、C1q（阴性）	系膜区、内皮下	膜增生性肾炎	系膜区、内皮下沉积
2	IgG3-Kappa；团块状、颗粒状/毛细血管襻、系膜区	C3（+++）、C4（阴性）、C1q（阴性）	系膜区、内皮下，基底膜内偶见	膜增生性肾炎	系膜区、内皮下沉积
3	IgG3-Kappa；花瓣状/毛细血管襻、系膜区	C3（+++）、C4（阴性）、C1q（+/-）	系膜区、内皮下，个别基底膜内	膜增生性肾炎	系膜区、内皮下沉积

病例	免疫荧光		超微结构电子致密物位	光镜
病例	优势蛋白类型及位置	补体类型	超微结构电子致密物位	肾小球病变类型	嗜复红物质沉积位置
1	IgG2-Lambda；团块状/毛细血管襻、系膜区	C3（+）、C4（+/-）、C1q（阴性）	系膜区、内皮下	膜增生性肾炎	系膜区、内皮下沉积
2	IgG3-Kappa；团块状、颗粒状/毛细血管襻、系膜区	C3（+++）、C4（阴性）、C1q（阴性）	系膜区、内皮下，基底膜内偶见	膜增生性肾炎	系膜区、内皮下沉积
3	IgG3-Kappa；花瓣状/毛细血管襻、系膜区	C3（+++）、C4（阴性）、C1q（+/-）	系膜区、内皮下，个别基底膜内	膜增生性肾炎	系膜区、内皮下沉积

病例	治疗方案	不良反应	开始缓解时间	部分缓解时间	完全缓解时间	随访时间	目前情况
1	厄贝沙坦300 mg、达格列净10 mg每日1次口服+利妥昔单抗（第0、2周，6个月分别静脉滴注1 g）+甲泼尼龙片晨起20 mg口服，规律减量，6个月后停药+环磷酰胺每月0.8 g静脉滴注，维持1年	中性粒细胞、淋巴细胞轻度下降	第1个月	第3个月	第6个月	12个月	24 h UTP下降至0.2 g/d以内，SCr及镜下血尿恢复正常；厄贝沙坦+达格列净口服维持治疗
2	沙库巴曲缬沙坦100 mg每日2次口服+硼替佐米1.3 mg/m²第1、8、15、22天静脉滴注+环磷酰胺300 mg/m² 第1、8、15天静脉滴注+地塞米松40 mg第1~2、8~9、15~16、22~23天口服	无	第1个月	第2个月	第7个月	10个月	24 h UTP维持在0.15 g/d左右，SCr及镜下血尿恢复正常，沙库巴曲缬沙坦口服维持治疗
3	利妥昔单抗第0、2周分别静脉滴注1 g+环磷酰胺第0、2周分别静脉滴注0.4 g，此后每月单用环磷酰胺0.6 g静脉滴注，目前仍在维持治疗中	无	第1个月	第6个月	无	6个月	24 h UTP下降至1 g/d左右，SCr维持在200 μmol/L左右，厄贝沙坦口服维持治疗